meningococcal infections/nausea

Krækjan er vistuð á klemmuspjaldið

Veldu tegund tegund

9 niðurstöður

Presenting features of meningococcal disease, public health messages and media publicity: are they consistent?

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

OBJECTIVE To investigate whether the presenting features of meningococcal disease as promoted in public health awareness material and in the print media accurately reflect the clinical features in patients admitted to Auckland hospitals with meningococcal disease January 1998 to June

[Clinical characterization of cases with meningococcal disease by W135 group in Chile, 2012].

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

BACKGROUND During 2012 in Chile, there were 60 cases of serogroup W135 meningococcal disease, which accounts for 57.7% of identified serogroup cases. OBJECTIVE To describe main clinical features of patients with serogroup W135 meningococcal disease confirmed in 2012. METHODS Descriptive study of

[Gastrointestinal symptoms with meningococcal infection. Emergence of Neisseria meningitidis serogroup W.]

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

BACKGROUND Meningococcal disease usually presents as meningitis and/or septicaemia, but can also present as pneumonia or arthritis. Since 2000, a worldwide increase in meningococcal disease is reported which is caused by a new virulent clone of serogroup W (MenW:cc11). This subtype is more likely to

Presentation with gastrointestinal symptoms and high case fatality associated with group W meningococcal disease (MenW) in teenagers, England, July 2015 to January 2016.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Atypical clinical presentations associated with group W meningococcal disease (MenW) are well-described and include pneumonia, septic arthritis, endocarditis and epiglottitis/supraglottitis. Following anecdotal reports of teenagers presenting with predominantly gastrointestinal symptoms, we

Notes from the Field: Meningococcal Disease in an International Traveler on Eculizumab Therapy - United States, 2015.

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

On June 2, 2015, CDC was notified that a male airline passenger, aged 41 years, with a fever of 105.4°F, headache, nausea, photophobia, diarrhea, and vomiting, which began approximately 3 hours after departure, was arriving to San Francisco, California, on a flight from Frankfurt, Germany. His

Disseminated Gonococcal Infection Associated with Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria: A Case Report and Literature Review

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Eculizumab has been developed as a breakthrough treatment for paroxysmal nocturnal hemoglobinuria (PNH). Not only for breakthroughs, eculizumab therapy is also known to increase the risk of invasive meningococcal infection. It has also been recently reported that, although rarely, administration of

Safety of meningococcal B vaccine (4CMenB) in adolescents in Australia

Aðeins skráðir notendur geta þýtt greinar

Skráðu þig / skráðu þig

Background: Four-component meningococcal B (4CMenB) vaccine is licensed in many countries but has had limited use in adolescents despite this age group being at increased risk of meningococcal disease.

Minocycline for prophylaxis of infection with Neisseria meningitidis: high rate of side effects in recipients.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig

A high rate of side effects (mostly vestibular) was found among 83 people receiving prophylaxis with minocycline because of contact with a patient who had died of meningitis due to Neisseria meningitidis. Three groups of contacts received different lots of minocycline and different dosage regimens.

Eculizumab.
Aðeins skráðir notendur geta þýtt greinar
Skráðu þig / skráðu þig

OBJECTIVE The pharmacology, pharmacokinetics, indications, clinical efficacy, adverse effects, drug interactions, and dosage and administration of eculizumab are reviewed. CONCLUSIONS Eculizumab, a recombinant, humanized, monoclonal, immunoglobulin G antibody produced from murine myeloma cells, is

Skráðu þig á
facebook síðu okkar
Herbal & Natural Medicine
Heillasta gagnagrunnur lækningajurtanna sem studdur er af vísindum
Virkar á 55 tungumálum
Jurtalækningar studdir af vísindum
Jurtaviðurkenning eftir ímynd
Gagnvirkt GPS kort - merktu jurtir á staðsetningu (kemur fljótlega)
Lestu vísindarit sem tengjast leit þinni
Leitaðu að lækningajurtum eftir áhrifum þeirra
Skipuleggðu áhugamál þitt og vertu vakandi með fréttarannsóknum, klínískum rannsóknum og einkaleyfum
Sláðu inn einkenni eða sjúkdóm og lestu um jurtir sem gætu hjálpað, sláðu jurt og sjáðu sjúkdóma og einkenni sem hún er notuð við.
* Allar upplýsingar eru byggðar á birtum vísindarannsóknum